Dr. Laura Witte
The purpose of this article is to review the benefits of tamoxifen therapy in premenopausal women with estrogen-positive breast cancer at five- and ten years of treatment. A PubMed literature search was conducted using search terms premenopausal, estrogen-positive breast cancer, tamoxifen, endocrine therapy. There is a 47% reduction in breast cancer recurrence when tamoxifen is utilized for five years. However, when treatment with tamoxifen is extended to ten years, the recurrence rate decreases by fifty percent in the second five years. The use of tamoxifen for five years reduces the risk of the recurrence of estrogen-positive breast cancer. When used for ten years, there is a more significant reduction in the risk of recurrence by more than fifty percent.
Steele A. Extended use of Tamoxifen in estrogen-positive breast cancer: Does it work?. Lynchburg Journal of Medical Science. 2020; 2(3).
Available when accessing via a campus IP address or logged in with a University of Lynchburg email address.
Off-campus users can also use 'Off-campus Download' button above for access.